These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

767 related items for PubMed ID: 11761458

  • 1. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L.
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [Abstract] [Full Text] [Related]

  • 2. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 3. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
    Hector S, Nava ME, Clark K, Murphy M, Pendyala L.
    Cancer Lett; 2007 Jan 08; 245(1-2):195-204. PubMed ID: 16516375
    [Abstract] [Full Text] [Related]

  • 4. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
    Martelli L, Di Mario F, Ragazzi E, Apostoli P, Leone R, Perego P, Fumagalli G.
    Biochem Pharmacol; 2006 Sep 14; 72(6):693-700. PubMed ID: 16844093
    [Abstract] [Full Text] [Related]

  • 5. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Deqnah N, Yu JQ, Beale P, Fisher K, Huq F.
    Anticancer Res; 2012 Jan 14; 32(1):135-40. PubMed ID: 22213298
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K, Oshima T, Kobayashi T, Yamamoto N, Hayashi C, Matsumoto T, Miwa H.
    Anticancer Res; 2008 Jan 14; 28(4B):2087-92. PubMed ID: 18751380
    [Abstract] [Full Text] [Related]

  • 11. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D, Warnecke A, Kalayda GV, Kratz F, Jaehde U.
    J Control Release; 2008 Oct 21; 131(2):100-6. PubMed ID: 18691617
    [Abstract] [Full Text] [Related]

  • 12. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
    Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E.
    Int J Oncol; 2000 Mar 21; 16(3):555-60. PubMed ID: 10675489
    [Abstract] [Full Text] [Related]

  • 13. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
    Rennicke A, Voigt W, Mueller T, Fruehauf A, Schmoll HJ, Beyer C, Dempke W.
    Anticancer Res; 2005 Mar 21; 25(2A):1147-55. PubMed ID: 15868958
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and antitumour activity of a new trinuclear platinum compound [{cis-PtCl(NH3)2μ {trans-Pt(3-hydroxypyridine)2H2N(CH2)5NH2)2}] Cl4 in human ovarian cancer cells.
    Hamad SA, Beale P, Yu JQ, Huq F.
    Anticancer Res; 2014 Apr 21; 34(4):1923-9. PubMed ID: 24692727
    [Abstract] [Full Text] [Related]

  • 15. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
    Ekblad L, Kjellström J, Johnsson A.
    Anticancer Drugs; 2010 Jun 21; 21(5):523-31. PubMed ID: 20168208
    [Abstract] [Full Text] [Related]

  • 16. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
    Saris CP, van de Vaart PJ, Rietbroek RC, Blommaert FA.
    Carcinogenesis; 1996 Dec 21; 17(12):2763-9. PubMed ID: 9006117
    [Abstract] [Full Text] [Related]

  • 17. Analysis of cytotoxicities of platinum compounds.
    Goodisman J, Hagrman D, Tacka KA, Souid AK.
    Cancer Chemother Pharmacol; 2006 Jan 21; 57(2):257-67. PubMed ID: 16028101
    [Abstract] [Full Text] [Related]

  • 18. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
    Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E.
    Anticancer Res; 2000 Jan 21; 20(2A):645-52. PubMed ID: 10810335
    [Abstract] [Full Text] [Related]

  • 19. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
    Luo FR, Wyrick SD, Chaney SG.
    Oncol Res; 1998 Jan 21; 10(11-12):595-603. PubMed ID: 10367941
    [Abstract] [Full Text] [Related]

  • 20. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
    Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E.
    Cancer Res; 1993 Jan 15; 53(2):242-7. PubMed ID: 8417816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.